source
- Nuvig Therapeutics pauses CIDP trial of NVG-2089, cites enrollment and cost challengesNuvig Therapeutics, backed by major pharmaceutical partners, announced it is stopping development of its lead fusion protein NVG-2089 for chronic inflammatory demyelinating polyradiculoneuropathy (…
- Season 2 of The Progress Profile podcast spotlights Alzheimer’s research and patient-centered trial designThe Progress Profile: Alzheimer’s Research in Focus returns for a second season, offering conversations about Alzheimer’s disease and brain health. In the premiere episode, Dr. John Harrison, Dr.…